Privately-held Danish dermatology specialist LEO Pharma has presented new safety data on Adtralza (tralokinumab) at the European Academy of Dermatology and Venereology (EADV) Congress.
Adtralza is a high-affinity human monoclonal antibody developed to bind to and inhibit the interleukin-13 cytokine.
It is approved for the treatment of adults with moderate-to-severe atopic dermatitis in the European Union, Great Britain, Canada, the United Arab Emirates, and Switzerland. The drug is also approved in the USA under the tradename Adbry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze